tag:blogger.com,1999:blog-1645755035470344918.post1331643187815959262..comments2024-02-06T01:19:36.619-03:00Comments on Medicina Baseada em Evidências: Revista TIME - Falta de Embasamento CientíficoLuis Cláudio Correiahttp://www.blogger.com/profile/02909537501158073052noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-1645755035470344918.post-28892204600259294242010-04-11T00:57:39.188-03:002010-04-11T00:57:39.188-03:00Segue uma resposta embasada nas evidências.
Study...Segue uma resposta embasada nas evidências. <br />Study Question: Is statin therapy effective for primary prevention of cardiovascular disease (CVD) in women?<br />Methods: Data from the JUPITER study were used for this analysis. A total of 6,801 women ≥60 years, and 11,001 men ≥50 years were included in the study. All participants had a C-reactive protein level ≥2 mg/L and a low-density lipoprotein cholesterol <130 mg/dl. Subjects were randomized to rosuvastatin or placebo and followed for a median of 1.9 years. In addition, a meta-analysis of randomized placebo-controlled trials using statins for primary prevention among women was performed to examine additional trials, including JUPITER. A total of 20,147 women, mean age 60-69 years, were included in the meta-analysis. <br />Results: Absolute CVD event rates, per 100 person-years in JUPITER, were 0.57 for women randomized to rosuvastatin and 1.04 for women randomized to placebo, and 0.88 for men randomized to rosuvastatin and 1.54 for men randomized to placebo. The relative risk (RR) reduction was 0.54 (95% confidence interval [CI], 0.37-0.80) for women and 0.58 (95% CI, 0.45-0.73) for men. Among women participants from JUPITER, there was a significant reduction in revascularization/unstable angina and nonsignificant reductions in secondary events such as myocardial infarction, stroke, and death. In the meta-analysis of 13,154 women, a significant reduction in primary CVD events was observed with statins (RR, 0.63; 95% CI, 0.49-0.82) and a nonsignificant reduction in total mortality (RR, 0.78; 95% CI, 0.53-1.15).<br />Conclusions: The authors concluded that data from the JUPITER trial suggest that statins reduce primary CVD events among women, with a relative risk similar to that observed in men. Further data from a meta-analysis supported this conclusion.<br />Perspective: These data support the use of statins in primary prevention of CVD events among women, particularly those ages ≥60. Identification of long-term risk in women will assist clinicians in identifying women who will receive the greatest primary risk reduction from statin therapy. <br />Circulation 2010; 121: 1069-1077Neudson Gomesnoreply@blogger.comtag:blogger.com,1999:blog-1645755035470344918.post-28090096690829073522010-04-04T22:37:06.647-03:002010-04-04T22:37:06.647-03:00Excelente post (como sempre) Luis.
É extremamente...Excelente post (como sempre) Luis. <br />É extremamente importante corrigir as distorções da imprensa leiga e, principalmente, de forma substanciada como você o faz. A responsabilidade de imprensa é enorme e os danos causados podem ser muito grandes, até pela influência de parte menos crítica da comunidade médica.<br />Quanto à representação do sexo feminino nos estudos, recentemente foi publicado um estudo mostrando que há subrepresentação também nos estudos experimentais.<br />Wald, C., & Wu, C. (2010). Of Mice and Women: The Bias in Animal Models Science, 327 (5973), 1571-1572 DOI: 10.1126/science.327.5973.1571Anonymoushttps://www.blogger.com/profile/08131807453426268101noreply@blogger.com